<DOC>
	<DOCNO>NCT02769364</DOCNO>
	<brief_summary>Decision-making treatment metastatic breast cancer second line chemotherapy limit lack establish predictive factor benefit chemotherapy regimen . Eribulin emerge single agent demonstrate overall survival improvement third-line set beyond . The purpose study define clinical profile metastatic breast cancer participant achieve long-term benefit chemotherapy eribulin third-line set beyond .</brief_summary>
	<brief_title>Extended Treatment Metastatic Breast Cancer With Eribulin</brief_title>
	<detailed_description>This multicenter , retrospective , observational , case study analysis ass long-term eribulin treatment metastatic breast cancer . The study conduct 26 Spanish hospital participate national pre-market access program eribulin 2011 2014 . An exploratory comparison group short-term responder include similar observational study perform .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Participants Advanced Metastatic Breast Cancer Eribulin least 7 month Exclusion criterion : Lack accessible clinical record</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Metastatic Breast Cancer</keyword>
	<keyword>Eribulin</keyword>
</DOC>